Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 5,901 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 3 Clear all
Active, not recruiting Not applicable Interventional

Is the Degree of Perceived Effort During Resistance Exercise Important for Improvements in Blood Glucose

NCT06208189
View directory record Official record
Conditions
PreDiabetes, Type 2 Diabetes Mellitus
Interventions
High-effort session, Low-effort session, Control
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 23, 2026, 2:15 AM EDT
Terminated Phase 1 Interventional Results available

Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy

NCT01405950
View directory record Official record
Conditions
Spasticity Due to Cerebral Palsy
Interventions
Zanaflex Capsules
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
2 Years to 16 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 23, 2026, 2:15 AM EDT
Recruiting Phase 1 Interventional

A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

NCT07148089
View directory record Official record
Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
SGT-501
Drug
Lead sponsor
Solid Biosciences Inc.
Industry
Eligibility
7 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy Evaluation of the Xerf Device for Aesthetic Treatments

NCT07585591
View directory record Official record
Conditions
Facial Aging, Facial Skin Laxity, Submental and Neck Skin Laxity
Interventions
Noninvasive dual-frequency monopolar radiofrequency
Device
Lead sponsor
CynosureLutronic
Industry
Eligibility
22 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
4
States / cities
Naperville, Illinois • Hunt Valley, Maryland • Montclair, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Not applicable Interventional Results available

Novel Web-based, Self-directed Intervention for Chronic Pelvic Pain

NCT06352840
View directory record Official record
Conditions
Chronic Pelvic Pain, Endometriosis
Interventions
My Pelvic Plan Website, Control Group website
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 2:15 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

NCT00195091
View directory record Official record
Conditions
Breast Cancer
Interventions
Tetrathiomolybdate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 23, 2026, 2:15 AM EDT
Terminated Phase 1 Interventional

Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma

NCT00383097
View directory record Official record
Conditions
Hodgkins Lymphoma, Non-Hodgkin Lymphoma
Interventions
LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES, LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

NCT00877110
View directory record Official record
Conditions
Neuroblastoma, Bone Marrow, Sympathetic Nervous System
Interventions
cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Not applicable Interventional

Home Exercise Program for Homebound Older Adults

NCT04034888
View directory record Official record
Conditions
Aging
Interventions
HEX
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
65 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 23, 2026, 2:15 AM EDT
Recruiting Not applicable Interventional

Reach Through Equitable Implementation in Utah

NCT06881069
View directory record Official record
Conditions
Tobacco Use Cessation, Tobacco Use, Tobacco Smoking, Tobacco Chewing, Tobacco Dependence
Interventions
Clinic Level: AAC - SDOH, AAC - Tobacco, Non-Bundled, Bundled, Dose 1, Dose 3, Dose 6, Dose 9, Dose 12, RPN, PPN
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
1,560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 23, 2026, 2:15 AM EDT
Terminated Phase 1 Interventional

Continued Treatment for Participants Enrolled in Studies of BXQ-350

NCT04404569
View directory record Official record
Conditions
Neoplasms
Interventions
BXQ-350
Drug
Lead sponsor
Bexion Pharmaceuticals, Inc.
Industry
Eligibility
1 Year and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Lexington, Kentucky • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

NCT02141542
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Tremelimumab, MEDI3617
Drug
Lead sponsor
F. Stephen Hodi, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease

NCT03533673
View directory record Official record
Conditions
Pompe Disease
Interventions
ACTUS-101
Genetic
Lead sponsor
AskBio Inc
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 2:15 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Reading Outcomes in Children With Vestibular Loss

NCT05414903
View directory record Official record
Conditions
Vestibular Disorder, Hearing Loss, Sensorineural
Interventions
Dynamic Visual Acuity, Reading Outcomes, Static Visual Acuity
Behavioral
Lead sponsor
Father Flanagan's Boys' Home
Other
Eligibility
7 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Not applicable Interventional

Prematurity Related Ventilatory Control (PRE-VENT) - Specific Aim 2

NCT03333161
View directory record Official record
Conditions
Infant,Premature
Interventions
Cardiorespiratory monitoring
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 15 Days
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Phase 1 Interventional Results available

Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy

NCT02342223
View directory record Official record
Conditions
HIV Facial Lipoatrophy
Interventions
Voluma
Device
Lead sponsor
Jared Jagdeo, MD, MS
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Mather, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 23, 2026, 2:15 AM EDT
Not yet recruiting Phase 2 Interventional

Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)

NCT06084780
View directory record Official record
Conditions
Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum, Pseudomyxoma Peritonei
Interventions
Intestinal, Multivisceral or Modified Multivisceral Transplantation, Alemtuzumab, Tacrolimus, Sirolimus
Procedure · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies

NCT01677559
View directory record Official record
Conditions
Adenocarcinoma, Pancreatic Neoplasms
Interventions
MLN8237, nab-Paclitaxel
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Not applicable Interventional

Physical Activity as Self-Management Approach to Improve Health Outcomes in AML

NCT02584296
View directory record Official record
Conditions
Leukemia, Myeloid, Monocytic
Interventions
BSMA
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 23, 2026, 2:15 AM EDT
Recruiting Phase 1 Interventional

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

NCT07121946
View directory record Official record
Conditions
Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL)
Interventions
LTZ-301
Biological
Lead sponsor
LTZ Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Duarte, California • St Louis, Missouri • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 23, 2026, 2:15 AM EDT
Active, not recruiting Not applicable Interventional

A Study of a Pelvic Floor Muscle Exercise Program Before and After Radical Prostatectomy

NCT06671782
View directory record Official record
Conditions
Prostate Cancer
Interventions
Kegel exercises, Pelvic Floor Muscle Exercise Program with biofeedback, Questionnaires, Interviews
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 23, 2026, 2:15 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

RHA® Redensity With New Anesthetic Agent Perioral Rhytids (PAS)

NCT06378086
View directory record Official record
Conditions
Pain, Aging
Interventions
RHA® Redensity with new anesthetic agent, RHA® Redensity with lidocaine
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Not applicable Interventional

Implementation of a System-level Tobacco Treatment Intervention

NCT02816697
View directory record Official record
Conditions
Smoking Cessation, Lung Cancer
Interventions
CEASE, Usual Care Tobacco Treatment Services
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Not applicable Interventional Results available

Decision Support for Intraoperative Low Blood Pressure

NCT02726620
View directory record Official record
Conditions
Hypotension
Interventions
Attending real-time decision support, In-room real-time decision support, Attending feedback emails, In-room provider feedback emails, Anesthesia Information Management System (AIMS), Perioperative Data Warehouse (PDW), General anesthesia, Pager system, Central neuraxial anesthesia, Non-cardiac surgery, Propofol, Sevoflurane, Desflurane, Isoflurane, Ephedrine, Phenylephrine, Norepinephrine, Epinephrine, Dobutamine, Dopamine, Isoproterenol, Milrinone, Atropine, Glycopyrrolate, Vasopressin, Terlipressin, Sodium Chloride 0.9%, Ringer's lactate, Hydroxyethyl starch solutions, Fresh Frozen Plasma, Packed Red Blood Cells, Albumin solutions, Plasma-Lyte, Lidocaine, Bupivacaine, Levobupivacaine, Ropivacaine, Mepivacaine, Tetracaine, Prilocaine, Procaine, Chloroprocaine, Benzocaine, Articaine
Procedure · Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years to 100 Years
Enrollment
22,435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 23, 2026, 2:15 AM EDT